v3.26.1
Organization and Description of Business (Details Narrative) - USD ($)
 1 Months Ended 6 Months Ended 12 Months Ended
Jul. 20, 2026
Jun. 26, 2026
May 20, 2026
Oct. 24, 2025
Aug. 14, 2026
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Aug. 25, 2026
Aug. 06, 2026
Feb. 26, 2026
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Sale of Stock, Consideration Received on Transaction               $ 22,251      
Common stock, par value           $ 0.0001   $ 0.0001      
Sale of Stock, Number of Shares Issued in Transaction   213,333           267      
Sale of Stock, Price Per Share           $ 36.34          
Proceeds before offering expenses           $ 1,860,000        
Minimum closing bid price                 $ 1.00   $ 1.00
Market value of listed securities closed                     $ 35,000,000
Escrow deposit           600,000          
Adjustment common stock and additional paid in capital           $ 4,919   $ 3,399      
Subsequent Event [Member]                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Common stock, par value                   $ 0.0001  
Pharm Ala Biotech Holdings Inc. [Member]                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Aggregate payment amount $ 3,333,333                    
Initial cash consideration 1,500,000                    
Escrow deposit 600,000                    
Payable share value 1,833,333                    
Development milestone payments $ 23,333,333                    
Development milestone payment description (i) $3,333,333 upon first dosing of the first patient in a Phase 3 clinical trial of a Licensed Product in the Territory (payable fifty percent (50%) in cash and fifty percent (50%), at PharmAla’s election, in cash or common stock) and (ii) $20,000,000 upon first FDA approval of an NDA for a Licensed Pr6oduct (payable in cash).                    
Commercialization milestone payments $ 73,333,333                    
Commercialization milestone payment description (i) $10,000,000 upon first achievement of $333,333,333 in net sales in the Territory, (ii) $30,000,000 upon first achievement of $1,000,000,000 in net sales in the Territory, and (iii) $33,333,333 upon first achievement of $2,000,000,000 in net sales in the Territory.                    
Common Stock [Member] | Subsequent Event [Member]                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Sale of Stock, Price Per Share         $ 13.55            
Payable share value         $ 1,428,864            
Standby Equity Purchase Agreement [Member]                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Common stock, par value       $ 0.0001              
Standby Equity Purchase Agreement [Member] | Maximum [Member]                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Sale of Stock, Consideration Received on Transaction       $ 20,000,000.0              
Securities Purchase Agreement [Member] | Common Stock [Member]                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Sale of Stock, Consideration Received on Transaction     $ 2,000,000.0                
Sale of Stock, Number of Shares Issued in Transaction     95,238                
Sale of Stock, Price Per Share     $ 21.00                
Placement agent fees     $ 140,000                
Proceeds before offering expenses     $ 1,860,000